Trial Profile
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2017
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Allergan
- 02 Sep 2011 Results presented at the 41st Annual Meeting of the International Continence Society.
- 17 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual patient number (74) added as reported by ClinicalTrials.gov.